Davies P R, Warwick P, O'Connor M
Pain Management Service, Princess Margaret Hospital, Swindon.
Anaesthesia. 1996 Sep;51(9):880-2. doi: 10.1111/j.1365-2044.1996.tb12625.x.
A double-blind, randomised, placebo-controlled study was performed to assess the antiemetic efficacy of ondansetron in women receiving morphine from a patient-controlled analgesia system after total abdominal hysterectomy. Sixty-six ASA grade 1 or 2 patients scheduled for total abdominal hysterectomy were randomly allocated into one of two groups. All patients received a standardised anaesthetic and postoperative patient-controlled analgesia regimen. Group 1 received ondansetron 4 mg at induction of anaesthesia, repeated 8 h later. Group 2 received saline as a placebo at the same times. Pain scores, nausea scores, episodes of vomiting, use of rescue antiemetics and recollection of nausea and vomiting were not different between the groups. Only 15% of patients who received ondansetron and 30% of patients who received the placebo recorded no nausea or vomiting in the first 24 h. We conclude that ondansetron, in the dose studied, does not reduce nausea and vomiting in women receiving morphine from a patient-controlled analgesia system after total abdominal hysterectomy.
一项双盲、随机、安慰剂对照研究旨在评估昂丹司琼对全腹子宫切除术后采用患者自控镇痛系统接受吗啡治疗的女性的止吐效果。66例计划行全腹子宫切除术的ASA 1或2级患者被随机分为两组。所有患者均接受标准化麻醉和术后患者自控镇痛方案。第1组在麻醉诱导时给予昂丹司琼4 mg，8小时后重复给药。第2组在相同时间给予生理盐水作为安慰剂。两组之间的疼痛评分、恶心评分、呕吐发作次数、使用急救止吐药情况以及对恶心和呕吐的回忆均无差异。在最初24小时内，接受昂丹司琼治疗的患者中只有15%、接受安慰剂治疗的患者中只有30%未出现恶心或呕吐。我们得出结论，在所研究的剂量下，昂丹司琼并不能减少全腹子宫切除术后采用患者自控镇痛系统接受吗啡治疗的女性的恶心和呕吐。
